Gene symbol | F | Synonyms | None | Type of gene | protein-coding |
Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | |
Description | Fusion protein (F) |
GTO ID | GTC1625 |
Trial ID | NCT02830932 |
Disease | Respiratory Syncytial Virus Infectious Disease |
Altered gene | F |
Therapeutic/Target gene | Therapeutic gene |
Therapy | dsRNA |
Treatment | VXA-RSV-f |
Phase | Phase1 |
Recruitment status | Completed |
Title | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers |
Year | 2016 |
Country | United States |
Company sponsor | Vaxart |
Other ID(s) | VXA-RSV-101 |
Vector information | |||||||
|
Cohort1: VXA-RSV-f_dose level 2 | |||||||
|
|||||||
Cohort2: VXA-RSV-f_dose level 1 | |||||||
|
|||||||
Cohort3: Placebo | |||||||
|